临床试验/ACTRN12608000434392

ACTRN12608000434392已完成未知

ACTIVE MANAGEMENT OF THE THIRD STAGE OF LABOUR WITHOUT CONTROLLED CORD TRACTION FOR PREVENTING POSTPARTUM HAEMORRHAGE: A RANDOMIZED NON-INFERIORITY CONTROLLED TRIA

World Health Organization0 个研究点目标入组 25,000 人开始时间: 2008年8月29日最近更新: 2020年1月13日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方: World Health Organization
入组人数: 25,000

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomised controlled trial
主要目的: Prevention
盲法: Blinded (masking used)

入排标准

年龄范围: 15 Years 至 49 Years（—）
性别: Female

入选标准

•pregnant women deliverying vaginally

排除标准

•1.Advanced first stage of labour (> 6 cm cervical dilatation)
•2.Women who are too distressed to give consent regardless of cervical dilatation or phase of labour. Such evaluation will be made by the clinician in charge of the care of the woman.
•3.Minors without a guardian
•4.Planned caesarean section
•5.If the birth is considered an abortion according to local limits
•6.Women with twins or higher order multiple gestations
•7.Women who are not capable of giving consent due to other health problems such as obstetric emergencies (e.g. eclampsia) or mental disorder.

研究者

发起方

World Health Organization

相似试验

Active management of the third stage of labor: Uterine Tonus Assessment by Midwife vs. Patient self-administratioPregnancy and ChildbirthPostpartum hemorrhage

PACTR201402000736158Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht800

Active versus expectant management of third stage of labour: the Hinchingbrooke randomised controlled trialPregnancy and childbirth: ChildbirthPregnancy and Childbirth

ISRCTN63422923HS R&D Regional Programme Register - Department of Health (UK)1,512

A PHASE 3, 40-WEEK, ACTIVE-CONTROLLED, DOUBLE-BLIND EXTENSION STUDY OF PRELADENANT IN SUBJECTS WITH MODERATE TO SEVERE PARKINSON´S DISEASE (PHASE 3, PROTOCOL N° P06153)

PER-038-11SCHERING PLOUGH RESEARCH INSTITUTE,

An Active-Controlled Extension Study to P04938 and P07037 (Study P06153 AM3)

CTRI/2012/07/002811Merck Sharp Dohme750

A PHASE 3, DOUBLE-BLIND, PLACEBO-AND ACTIVE-CONTROLLED DOSE RANGE-FINDING EFFICACY AND SAFETY STUDY OF PRELADENANT IN SUBJECTS WITH EARLY PARKINSON´S DISEASE (PHASE 3 PROTOCOL N°. P05664)-G20 Parkinson´s diseaseParkinson´s diseaseG20

PER-082-10SCHERING PLOUGH RESEARCH INSTITUTE,